Company MolMed S.p.A.

Molecular Medicine SpA (MolMed) is an Italy-based company engaged in the medical biotechnology sector. The Company is active in the research, development and clinical validation of therapies for the treatment of cancer. The Company's activities include identification and development of bio-pharmaceuticals reducing the tumor mass and slowing down its growth, as well as the development of selective therapies to eliminate residual tumor tissue. MolMed's pipeline comprises two main investigational anticancer therapies: TK, which is a cell-based therapy for the treatment of leukemia, and NGR-hTNF, which is a biological drug targeting tumor blood vessels for the treatment of solid tumors. MolMed develops, conducts and validates custom studies, creating testing procedures and addressing the test specifications required for cell-based therapies. It is also active in the production of cell-based medicinal products used in clinical trials and drug development of cell-based therapies.